| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.016 | 0.6 |